REQUEST FOR THE PROPOSAL No. 38/2021-ARG – Phase I, First-in-Human type, clinical trial

The order is carried out as a part of the project titled:
– ARG: „PRE-CLINICAL AND CLINICAL DEVELOPMENT OF ARGINASE INHBITOR FOR CANCER IMMUNOTHERAPY” (POIR.01.01.01-00-415/17)

co-financed by the European Union Funds and carried out on the basis of the competitiveness principle

We hereby look for Contractor ready to perform: Organization and comprehensive execution of the phase I, First-in-Human type, clinical trial for a OATD-02 compound.

38_2021_Request_ENG

38_2021_Appendices_1_2_3_4_ENG

On September 28, 2021, the Ordering Party updated the Request, Appendices 1 and 6. The changes are marked in red and appropriately crossed out. In addition, the Ordering Party provides answers to questions that arose by the set deadline. Answers to the questions provided by the Ordering Party constitute an integral part of the documentation concerning the tender procedure. The deadline for submitting offers has been extended to October 15, 2021, at 08:00 am (CET).

38_2021_Request_ENG_28.09.2021_final

38_2021_Appendices_1_2_3_4_ENG_28.09.2021_final

Questions to the Request for Proposal No. 38_2021 – final

Kinga KazimierczakREQUEST FOR THE PROPOSAL No. 38/2021-ARG – Phase I, First-in-Human type, clinical trial